The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
Winger, J.A., Hantschel, O., Superti-Furga, G., Kuriyan, J.(2009) BMC Struct Biol 9: 7-7
- PubMed: 19236722 
- DOI: https://doi.org/10.1186/1472-6807-9-7
- Primary Citation of Related Structures:  
3FW1 - PubMed Abstract: 
Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxidoreductase NQO2, a flavoprotein that is phosphorylated in a chronic myelogenous leukemia cell line.
Organizational Affiliation: 
Department of Molecular and Cell Biology, California Institute for Quantitative Biosciences, Howard Hughes Medical Institute, University of California, Berkeley, USA. wingerj@berkeley.edu